Flucloxacillin
500mg and 1000mg injection, oral mixture
© Department for Health and Ageing, Government of South Australia. All rights reserved.

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms
Floxacillin

Dose and Indications

Infection Due To Susceptible Gram Positive Organisms

Intravenous, Intramuscular
50mg/kg/dose
(100mg/kg/dose in staphylococcal osteomyelitis, meningitis or a cerebral abscess)

Oral
25mg/kg/dose

Corrected Age (weeks)

<table>
<thead>
<tr>
<th>Postnatal age (days)</th>
<th>Frequency (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;7</td>
<td>every 12 hours</td>
</tr>
<tr>
<td>7 to 20</td>
<td>every 8 hours</td>
</tr>
<tr>
<td>≥ 21</td>
<td>every 6 hours</td>
</tr>
</tbody>
</table>

Infectious Disease (ID) advice should be sought for proven sepsis to guide duration of therapy.
Preparation and Administration

**Intravenous**

There are **TWO STEPS** to this process.

| STEP ONE: Reconstitute the flucloxacillin vial according to the table. |
|-------------------|-------------------|-------------------|
| **Vial Strength**  | **Volume of Water for Injection** | **Final Concentration of** |
| (mg)              | (WFI) to add (mL)  | flucloxacillin (mg/mL) |
| 500mg             | 4.6mL             | 100mg/mL           |
| 1000mg            | 9.3mL             | 100mg/mL           |

**STEP TWO:** Further dilute 5mL of the 100mg/mL flucloxacillin solution with 5mL of compatible fluid (to a total volume of 10mL). The resulting solution contains 50mg/mL flucloxacillin.

**Example calculation table:**

<table>
<thead>
<tr>
<th>Dose</th>
<th>25mg</th>
<th>50mg</th>
<th>75mg</th>
<th>100mg</th>
<th>125mg</th>
<th>150mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.5mL</td>
<td>1mL</td>
<td>1.5mL</td>
<td>2mL</td>
<td>2.5mL</td>
<td>3mL</td>
</tr>
</tbody>
</table>

Infuse over 30 minutes or administer as a bolus over 3-5 minutes.

**Flucloxacillin is an irritant therefore infusion is the preferred method of administration.**

Discard remaining solution

**Oral**

Oral doses should be given on an empty stomach, where possible.

**Intramuscular**

<table>
<thead>
<tr>
<th>Vial Strength</th>
<th>Volume of WFI to add (mL)</th>
<th>Final Concentration of flucloxacillin (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>500mg</td>
<td>1.6mL</td>
<td>250mg/mL</td>
</tr>
<tr>
<td>1000mg</td>
<td>3.3mL</td>
<td>250mg/mL</td>
</tr>
</tbody>
</table>

**Example calculation table:**

<table>
<thead>
<tr>
<th>Dose</th>
<th>25mg</th>
<th>50mg</th>
<th>75mg</th>
<th>100mg</th>
<th>125mg</th>
<th>150mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1mL</td>
<td>0.2mL</td>
<td>0.3mL</td>
<td>0.4mL</td>
<td>0.5mL</td>
<td>0.6mL</td>
</tr>
</tbody>
</table>
South Australian Neonatal Medication Guidelines

Flucloxacillin
500mg and 1000mg injection, oral mixture

Compatible Fluids
Glucose 5%, sodium chloride 0.9%

Adverse Effects

Common
Diarrhoea, pain and inflammation at injection site, transient increases in liver enzymes and bilirubin

Infrequent
Vomiting, Clostridium difficile-associated disease

Rare
Black tongue, electrolyte disturbances, neurotoxicity, bleeding, blood dyscrasias, hepatic reactions, including severe cholestatic hepatitis (especially in treatment >2 weeks).
Anaphylactic shock is not commonly seen in the neonates

Monitoring
> Observe intravenous site for extravasations
> Periodic liver function tests on long term therapy (>14 days).

Practice Points
> There have been reports of severe, delayed cholestatic jaundice in adults particularly after treatment for more than 2 weeks. While this has not been recognised with neonatal use, caution would be recommended in this population.

References
South Australian Neonatal Medication Guidelines

Flucloxacillin

500mg and 1000mg injection, oral mixture

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: SA Health Safety and Quality Strategic Governance Committee
Next review due: 24 May 2023
ISBN number: 978-1-74243-921-1
PDS reference: CG027
Policy history: Is this a new policy (V1)? N
Does this policy amend or update and existing policy? Y
If so, which version? V3
Does this policy replace another policy with a different title? Y
If so, which policy (title)? Flucloxacillin

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>24/5/18</td>
<td>V4</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Formally reviewed in line with 5 year scheduled timeline for review.</td>
</tr>
<tr>
<td>12/8/14</td>
<td>V3</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Minor amendment</td>
</tr>
<tr>
<td>17/6/14</td>
<td>V2</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Formally reviewed in line with 3 year scheduled timeline for review.</td>
</tr>
<tr>
<td>1/11/12</td>
<td>V1</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Original SA Health Safety and Quality Strategic Governance Committee</td>
</tr>
</tbody>
</table>